Ad
related to: hcv polymerase inhibitors
Search results
Results From The WOW.Com Content Network
The virus is internalized and the nucleocapsid is released into the cytoplasm of the hepatocyte after binding with the receptor. The NS5B protein, which is an RNA-dependent RNA polymerase, catalyzes hepatitis C virus replication. [10] The hepatitis C virus can cause acute infection but most patients are asymptomatic upon exposure.
The HCV genome. NS5A in the bottom row, second from the right. Nonstructural protein 5A (NS5A) inhibitors are direct acting antiviral agents (DAAs) that target viral proteins, and their development was a culmination of increased understanding of the viral life cycle combined with advances in drug discovery technology.
HCV genome. Nonstructural protein 5B (NS5B) is a viral protein found in the hepatitis C virus (HCV). [1] It is an RNA-dependent RNA polymerase, having the key function of replicating HCV's viral RNA by using the viral positive RNA strand as a template to catalyze the polymerization of ribonucleoside triphosphates (rNTP) during RNA replication.
It contains sofosbuvir, a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor; velpatasvir, an HCV NS5A inhibitor; and voxilaprevir an HCV NS3/4A protease inhibitor. [ 2 ] [ 5 ] The most common adverse reactions include headache, fatigue, diarrhea, and nausea.
It is also possible that NS5A is a critical component during HCV replication and subcellular localization, which may shed light on the poorly understood HCV life cycle. [1] [4] Additionally, NS5A has been shown to modulate the polymerase activity of NS5B, an RNA-dependent RNA polymerase (RdRp). [3]
For example, for the treatment of genotypes 1, 4, 5, and 6 hepatitis C infections, sofosbuvir can be used in combination with the viral NS5A inhibitor ledipasvir. [16] In genotype 2 and 3 HCV infections, sofosbuvir can be used in combination with daclatasvir. For the treatment of cases with cirrhosis or liver transplant patients, weight-based ...
Coblopasvir is a pharmaceutical drug for the treatment of hepatitis C. [1] It is a pan-genotypic inhibitor of HCV nonstructural protein 5A. [2]In China, it is approved for use in combination with sofosbuvir for treating naïve or interferonâexperienced adults chronically monoinfected patients with HCV of genotype 1, 2, 3 and 6, with or without compensated cirrhosis.
IDX-184 is an antiviral drug which was developed as a treatment for hepatitis C, acting as a NS5B RNA polymerase inhibitor. [1] [2] While it showed reasonable effectiveness in early clinical trials it did not progress past Phase IIb. [3]